ACCESS Newswire

Megola, Inc.

Share
Update: Megola Inc CEO Issues Letter to Shareholders

COVID delays now behind; company moving plans forward with EPA, FDA, 3rd Party Product Certifications

LAS VEGAS, NV / ACCESSWIRE / August 10, 2021 / Megola Inc. (OTC PINK:MGON) (the "Company"), is a Consortium Group of Health Technologies and Service Company. Megola, through product and technology acquisitions, has grown to have its own E-commerce Branding Division, Service Department, Licensing Division, Franchise Division all maintaining Megola's diverse manufactured product portfolios which allows the company to integrate into several vertical sales markets worldwide. Megola controls every aspect from manufacturing to distribution of all the patented, IP product lines giving it the best-case scenario in every competitive market space. Megola's team oversees all quality controls, product registrations and ensures customer satisfaction along with generating excellent shareholder value and growth. Megola is excited to be able to help the health and well being of people throughout the world in a conscious eco-friendly approach. As the world continues to become more "green" focused and a greater emphasis is placed on identifying environmentally sound solutions, Megola will benefit from our unwavering vision of providing superior solutions that support a sustainable future for all.

Dear Megola Shareholders,

Though we left behind our 2020 Year Ending March 31, 2021 and emerged as a stronger renewed company that is even more resolute in our dedication to Health and Wellness Technologies. The lingering effects of last year's challenges have resulted in delays in finalizing the additional acquisitions and some product certifications. But, as the effects of the pandemic are clearing, we are getting extremely excited to make the purchases announced earlier a reality during these next coming quarters.

Previously the Company announced upcoming additional product lines of NEXT GENERATION Antimicrobials including a 90-day Surface/Air Protection, a non-alcohol, non-benzalkonium based 24-hour Hand Purifier, a line of specialty coffees including a CDB blend, Weight loss blend, Libido blend, and an Energy/Wellness blend.

Also discussed was a development of a CBD gum line, infused CBD alcohol spirits line, additional CBD tinctures, creams, and edibles for our Balanced2Day brand line.

Megola Inc. has never lost sight of these commitments to these Health and Wellness product lines. These will be acquired, further developed and added to our Brand lines for retail and also introduced to partnerships for distribution and licensing.

Among other major goals that will set the course of our company we have been in discussions for obtaining and renew of past product lines from Megola Inc. These lines consist of Fire Inhibitors and Antimicrobials for treated wood products (formerly known as RedShield), Fire-Gel for lithium batteries, an Organic Bedbug/Dustmite/Antimicrobial 90-day blend and other fire related products that will be mentioned in future news releases.

Starting this quarter and beyond we want to assure our shareholders and customers that we are fully dedicated to bringing our products to market with outstanding results that make a difference in people's lives and their environments.

As your CEO, we want to under promise and over deliver and make this world a better place than we found it.

All the best,
Bob Gardiner,
President, CEO
Megola, Inc.

Contacts
For further information, contact:
John MacLeod
http://megolacorp.com
http://twitter.com/megolacorp
megola2020@gmail.com
1-888-587-1698

Stock information here: https://www.otcmarkets.com/stock/MGON/overview

Disclaimer: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. These forward-looking statements are based largely on the expectations or forecasts of future events, can be affected by inaccurate assumptions, and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the control of management. Therefore, actual results could differ materially from the forward-looking statements contained in this press release. Additional information respecting the factors that could materially affect the Company and its operations are contained in its annual report on Form 10K and Form 10-Q as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statement.

SOURCE: Megola, Inc.



View source version on accesswire.com:
https://www.accesswire.com/659060/Update-Megola-Inc-CEO-Issues-Letter-to-Shareholders

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

IXOPAY Appoints George Hansen as Chief Revenue Officer to Accelerate Global Growth in Tokenization, Orchestration, and Compliance18.11.2025 06:00:00 CET | Press release

Seasoned payments executive joins IXOPAY to lead global revenue strategy amid rapid growth and the rise of agentic commerce. LEHI, UTAH / ACCESS Newswire / November 18, 2025 / IXOPAY, a global leader in enterprise-grade payment orchestration, today announced the appointment of George Hansen as Chief Revenue Officer (CRO). A veteran of the payments and fintech industries, Hansen brings more than two decades of leadership experience driving growth, transformation, and customer-centric innovation at a global scale. In his new role, Hansen will drive IXOPAY's global revenue strategy, leading sales and partnerships and aligning with marketing and customer success to support enterprise merchants and partners worldwide. His appointment reinforces IXOPAY's commitment to giving merchants full control of their payment strategy through a vendor-neutral architecture designed for scale, flexibility, and intelligence. Hansen has held senior leadership positions at companies including American Expres

General Holdings Limited and NewOak Capital Form Strategic Joint Venture to Launch CMXG, an $800M Commodities Investment Platform18.11.2025 06:00:00 CET | Press release

DUBAI, AE / ACCESS Newswire / November 18, 2025 / General Holdings Limited (GH), a Dubai International Financial Centre-based multi-strategy private investment holding company, and NewOak Capital LLC, a New York collateralized private debt asset management and structured financing and capital markets firm, today announced the formation of Common Commodities CMXG (CMXG), a vertically integrated tech-enabled commodities investment platform designed to deliver risk-controlled, scalable institutional commodity-linked real yield and growth equity to qualified global investors. The partnership combines General Holdings' strategic capital and governance expertise with NewOak Capital's structured asset-based supply-chain financing capabilities and distribution platform. This sets the foundation for "a globally scalable, integrated and transparent institutional trade finance platform facilitating sustainable and inclusive cross-regional growth." Strategic Capital Deployment and Fund Launch CMXG

OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma17.11.2025 13:00:00 CET | Press release

OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer. TAIPEI, TW / ACCESS Newswire / November 17, 2025 / OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling technology. Cholangiocarcinoma is a rare and lethal malignancy with fewer than 50,000 patients in the United States and a 5-year survival rate ranging from 2% and 23% depending on disease stage, histological subtype, and localization 1 . At present, there are no FDA approved ADC therapies for cholangiocarcinoma. To encourage the industry to develop new treatment options for rare diseases, the US FDA grants Orphan Drug Designation to exper

Camino Completes C$5.6 Million Investment with Strategic Investors17.11.2025 12:00:00 CET | Press release

VANCOUVER, BC / ACCESS Newswire / November 17, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC:CAMZF) ("Camino" or the "Company") is pleased to announce the closing of its -brokered private placement (the "Financing") of common shares in the capital of the Company (the "Shares") previously announced in its news release dated November 12, 2025. Under the Financing, the Company issued an aggregate of 15,554,666 Shares at an issue price of $0.36 per Share, for aggregate gross proceeds of C$5,599,680. Participants in the Financing included two new key shareholders, Elemental Royalties (formerly EMX Royalty Corp.) and Continental General Insurance Company, as well as certain insiders of Camino. The gross proceeds of the Financing will be applied towards corporate working capital, legal expenses, engineering studies, project development, and general administrative expenses. The Shares issued pursuant to the Financing are subject to a statutory hold period expiring on March 15, 2026, in acc

GA-ASI Completes Full-Scale Fatigue Test on MQ-9B17.11.2025 03:10:00 CET | Press release

MQ-9B's Third Lifetime Test Completes the FSF Testing Process With a Total of 120,000 Hours DUBAI, UAE / ACCESS Newswire / November 16, 2025 / On October 31, 2025, General Atomics Aeronautical Systems, Inc. (GA-ASI) completed its "third lifetime" of full-scale fatigue (FSF) testing for the MQ-9B Remotely Piloted Aircraft (RPA). Completion of FSF testing for the third and final lifetime includes a total of 120,000 operating hours (40,000+ flight hours per aircraft life) for the RPA and is a key milestone in validating the design of the airframe. The testing verifies the airframe structural integrity in support of certification to the NATO STANAG 4671 standard. The aim of the testing is to identify any potential structural deficiencies ahead of fleet usage and assist in developing inspection and maintenance schedules for the airframe. Test results will be used as documentation for certification and will form the basis for in-service inspections of structural components. "The completion o

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye